Liver transplantation for hepatocellular carcinoma

被引:131
作者
Schwartz, M [1 ]
机构
[1] Mt Sinai Sch Med, Dept Adult Liver Transplantat & Hepatobiliary Sur, Recanati Miller Transplantat Inst, New York, NY 10029 USA
关键词
D O I
10.1053/j.gastro.2004.09.041
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Because hepatocellular carcinoma (HCC) arises in cirrhotic livers and is often multifocal, transplantation seems to be a rational approach. Early results were poor, but current restrictive selection criteria can yield excellent results. Patients with 1 HCC nodule :55 cm in diameter, or 2-3 nodules less than or equal to 3cm, receive United Network Organ Sharing priority; nevertheless, dropout from the waiting list is common. Predictors of dropout include multiple tumors and tumors with a diameter > 3 cm. Nonsurgical methods are commonly used to prevent tumor progression and thus prevent dropout. Expanding selection criteria results in more patients with HCC being cured at the expense of a higher incidence of recurrence. Molecular/biologic information is beginning to be incorporated into current staging systems in order to better predict HCC recurrence. In considering liver transplantation, the impact of the underlying liver disease is an important consideration; recurrent hepatitis C after transplant lowers patient survival independent of tumor recurrence.
引用
收藏
页码:S268 / S276
页数:9
相关论文
共 25 条
[1]   A model to predict severe HCV-related disease following liver transplantation [J].
Berenguer, M ;
Crippin, J ;
Gish, R ;
Bass, N ;
Bostrom, A ;
Netto, G ;
Alonzo, J ;
Garcia-Kennedy, R ;
Rayón, JM ;
Wright, TL .
HEPATOLOGY, 2003, 38 (01) :34-41
[2]   LIVER RESECTION VERSUS TRANSPLANTATION FOR HEPATOCELLULAR-CARCINOMA IN CIRRHOTIC-PATIENTS [J].
BISMUTH, H ;
CHICHE, L ;
ADAM, R ;
CASTAING, D ;
DIAMOND, T ;
DENNISON, A .
ANNALS OF SURGERY, 1993, 218 (02) :145-151
[3]   Liver transplantation for hepatocellular carcinoma [J].
Bismuth, H ;
Majno, PE ;
Adam, R .
SEMINARS IN LIVER DISEASE, 1999, 19 (03) :311-322
[4]   Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma [J].
Chen, YJ ;
Yeh, SH ;
Chen, JT ;
Wu, CC ;
Hsu, MT ;
Tsai, SF ;
Chen, PJ ;
Lin, CH .
GASTROENTEROLOGY, 2000, 119 (02) :431-440
[5]   Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma [J].
Cillo, U ;
Vitale, A ;
Bassanello, M ;
Boccagni, P ;
Brolese, A ;
Zanus, G ;
Burra, P ;
Fagiuoli, S ;
Farinati, F ;
Rugge, M ;
D'Amico, DF .
ANNALS OF SURGERY, 2004, 239 (02) :150-159
[6]   Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma [J].
Finkelstein, SD ;
Marsh, W ;
Demetris, AJ ;
Swalsky, PA ;
Sasatomi, E ;
Bonham, A ;
Subotin, M ;
Dvorchik, I .
HEPATOLOGY, 2003, 37 (04) :871-879
[7]   Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors [J].
Gaglio, PJ ;
Malireddy, S ;
Levitt, BS ;
Lapointe-Rudow, D ;
Lefkowitch, J ;
Kinkhabwala, M ;
Russo, MW ;
Emond, JC ;
Brown, RS .
LIVER TRANSPLANTATION, 2003, 9 (10) :1028-1035
[8]   Hepatocellular carcinoma:: A prime indication for living donor liver transplantation [J].
Gondolesi, G ;
Muñoz, L ;
Matsumoto, C ;
Fishbein, T ;
Sheiner, P ;
Emre, S ;
Miller, C ;
Schwartz, ME .
JOURNAL OF GASTROINTESTINAL SURGERY, 2002, 6 (01) :102-107
[9]  
Hasegawa S, 1999, CANCER-AM CANCER SOC, V86, P1682, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1682::AID-CNCR9>3.0.CO
[10]  
2-6